| Literature DB >> 36031906 |
Lauren Elman1, Bora Youn2, Crystal M Proud3, Margaret R Frey4, Senda Ajroud-Driss5, M Eileen McCormick6, David Michelson7, Michael S Cartwright8, Terry Heiman-Patterson9, Joseph M Choi10, Aastha Chandak11, Artak Khachatryan12, Marta Martinez12, Angela D Paradis2.
Abstract
Limited evidence exists on real-world adherence to nusinersen for the treatment of spinal muscular atrophy (SMA). Data are presented from a multi-site retrospective chart review of 86 adults with SMA initiating nusinersen at nine US centers between January 2017 and February 2019. Seventy-nine (92%) adults remained on nusinersen during the study; 454 (92%) of 493 total nusinersen doses were received on time. Fifty-eight (67%) adults received all nusinersen doses on time. The majority of patients with at least one nonadherent dose resumed nusinersen on time. Most patients followed the dosing schedule across the loading and maintenance dose periods.Entities:
Keywords: Medication adherence; adults; antisense oligonucleotides; neuromuscular diseases; retrospective studies; spinal muscular atrophy
Mesh：
Substances：
Year: 2022 PMID： 36031906 PMCID： PMC9535601 DOI： 10.3233/JND-210768
Source DB: PubMed Journal: J Neuromuscul Dis